HomeGeneticsGeneDCTN1 gene
Back to Gene
DCTN1 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

DCTN1 gene

The DCTN1 gene provides instructions for making dynactin-1, a protein essential for intracellular transport and the health of nerve cell axons.

Normal Function

The DCTN1 gene provides instructions for making a protein called dynactin-1. At least two different versions of this protein are produced in cells: a larger version called p150-glued and a smaller version called p135.

Both versions interact with other proteins to form a complex called dynactin. This complex plays a critical role in cell division and the transport of materials within cells. The p150-glued subunit attaches (binds) to a protein called dynein (a motor protein) and to microtubules (a track-like system). Together, these components act like a conveyer belt to move materials within cells.

The dynactin complex is particularly important for the function of axons, which are long extensions of nerve cells (neurons). The complex is a critical part of a rapid transport system that supplies axons with materials to keep them healthy and functioning efficiently.

Health Conditions Related to Genetic Changes

Perry syndrome

At least five mutations in the DCTN1 gene have been found to cause Perry syndrome. This progressive brain disease is characterized by parkinsonism, psychiatric changes, weight loss, and abnormally slow breathing (hypoventilation).

Most of these mutations change single amino acids in the dynactin-1 protein, impairing the ability of p150-glued to bind to the dynactin complex and to microtubules. An incomplete dynactin complex has a reduced ability to transport materials within cells. Slow or abnormal transport causes neurons to malfunction and die, leading to the signs and symptoms of Perry syndrome.

Other disorders

  • Distal hereditary motor neuronopathy type VIIB: A mutation replacing glycine with serine at position 59 (Gly59Ser) is linked to this disorder, which causes breathing difficulties and progressive muscle weakness in the face, hands, feet, and legs. It is believed this mutation disturbs interactions between the dynactin complex and microtubules.
  • Frontotemporal dementia (FTD): A mutation replacing arginine with lysine at position 1101 (Arg1101Lys) is associated with FTD. This mutation likely alters the 3-dimensional shape of dynactin-1, impairing its binding and slowing the transport of materials needed for axon function and nerve impulse transmission.

Other Names for This Gene

  • 150 kDa dynein-associated polypeptide
  • DAP-150
  • DP-150
  • DYNA_HUMAN
  • dynactin 1
  • dynactin 1 (p150, glued homolog, Drosophila)

Frequently Asked Questions

Deep brain stimulation has been attempted in a small number of Perry syndrome patients with mixed and limited outcomes. While it may provide modest, short-term reduction in motor rigidity or tremor, it does not stop the underlying neurodegenerative axonal transport failure, nor does it improve the life-threatening respiratory failure, severe weight loss, or psychiatric manifestations. Treatment therefore remains predominantly supportive and focused on respiratory protection, nutritional support, and safety management.
The most critical complication is central hypoventilation, a form of respiratory failure where the brain's respiratory centers fail to signal breathing, particularly during sleep. Because this can cause sudden nocturnal death, patients diagnosed with Perry syndrome require urgent baseline and serial polysomnography (sleep studies) alongside continuous nocturnal pulse oximetry and capnography. Most patients eventually require nocturnal non-invasive positive pressure ventilation (BiPAP) or a tracheostomy to support breathing and prevent fatal hypoxemic events.
While DCTN1-associated parkinsonism presents with tremors, rigidity, and bradykinesia, it is characterized by an earlier average age of onset (often in the late 40s to 50s) and rapid functional decline. Unlike idiopathic Parkinson's disease, the parkinsonian symptoms in Perry syndrome often respond poorly or only transiently to levodopa therapy. Furthermore, the motor deficits are uniquely coupled with profound early apathy, severe treatment-resistant depression, and precipitous, unexplained weight loss due to hypothalamic dysfunction.
lthough both stem from DCTN1 mutations, distal hereditary motor neuropathy type VIIB (dHMN-VIIB) is distinguished by prominent early vocal cord paralysis, which causes hoarseness, stridor, or shortness of breath on exertion, followed years later by progressive weakness and muscle wasting primarily in the hands and lower legs. It lacks the severe psychiatric disturbances, central hypoventilation, and rapid parkinsonian deterioration seen in classic Perry syndrome.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss